

## LEUKOCARE to present at multiple European Conferences

LEUKOCARE AG to present at multiple conferences discussing viral vector stabilization as well as stabilization of biologics by applying artificial intelligence (AI) and an algorithm-based formulation development approach in combination with LEUKOCARE's SPS® technologies.

---

### **Munich, Germany, 09 April 2019**

Munich-based biotechnology company LEUKOCARE announced today that it has presented and will present at various conferences focusing on algorithm-based formulation development and the employment of artificial intelligence (AI) in drug product formulation.

At the 3<sup>rd</sup> European Conference on Pharmaceutics in Bologna which took place March 25-26, LEUKOCARE presented data on linear influence of single amino acids on viral vector stability and the predictability of thermal stress during accelerated aging for real time storage. Additional findings highlighted the strengths of LEUKOCARE's SPS® technologies enabling long-term liquid storage of viral vectors without evident loss of infectivity.

At the International Research Conference on Protein Stability and Interactions in Heidelberg which took place April 1-2, data were presented featuring LEUKOCARE's algorithm-based formulation approach including Design of Experiment (DoE) to generate superior liquid formulations of therapeutic antibodies.

Moreover, Dr Hauck, VP R&D at LEUKOCARE, will talk on how artificial intelligence and machine learning may replace wet lab in R&D development processes at the Deutsche Biotechnologietage in Würzburg on April 10. This presentation features LEUKOCARE's algorithm-based formulation development and the implementation of tools to move formulation development from *in vitro* to *in silico*.

"We are pleased to have the opportunity to present and share data in context to our novel algorithm-based approaches in formulation development at top-class events in the biotech sector. Artificial intelligence and machine learning are becoming vital aspects of drug development and we are convinced that these new approaches will also have beneficial effects on formulation development. By implementing database and AI into our SPS® formulation technology platform, we are able to provide to our customers superior drug product formulations for biopharmaceuticals, vaccines and viral vectors", said Michael Scholl, CEO at LEUKOCARE.

Following are the accepted presentations featuring LEUKOCARE at the 3<sup>rd</sup> *European Conference on Pharmaceutics*, the *International Research Conference on Protein Stability and Interactions* and the *Deutsche Biotechnologietage*:

1) LEUKOCARE AG: Effective Stabilization of Viral Vectors in Liquid using an Algorithm-based Development Approach, presented by Dr Sabine Hauck on Monday, March 25

2) LEUKOCARE AG: Algorithm-based formulation development including a DoE stability study enabling more stable liquid formulations of therapeutic antibodies, presented by Dr Kristina Kemter on Tuesday, April 2

3) LEUKOCARE AG: Shift *in vitro* to *in silico* - Replacing wet lab by AI in a biotech development process, presented by Dr Sabine Hauck on Wednesday, April 10

For more information, please visit:

[https://www.europeanmeeting.org/fileadmin/dateiablage/europeanmeeting/2019\\_Bologna/1119\\_third\\_announcement.pdf](https://www.europeanmeeting.org/fileadmin/dateiablage/europeanmeeting/2019_Bologna/1119_third_announcement.pdf)

[https://www.apv-mainz.de/fileadmin/dateiablage/apv-mainz/Seminare/oeffentlich/6777\\_PIPPI.pdf](https://www.apv-mainz.de/fileadmin/dateiablage/apv-mainz/Seminare/oeffentlich/6777_PIPPI.pdf)

<https://www.biotechnologietage.de/de/programm/biotech-medtech-und-it-konvergenz-oder-konkurrenz.html>

## **About LEUKOCARE AG**

LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS<sup>®</sup>) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE's SPS<sup>®</sup> technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation including high-concentration formulations. SPS<sup>®</sup> technologies also protect proteins in biologically functionalized combination devices.

[www.leukocare.com](http://www.leukocare.com)

Contact:  
Michael Scholl  
michael.scholl@leukocare.com  
+49 (0) 89 7801 6650